Catalyst Financial Partners LLC Trims Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Catalyst Financial Partners LLC reduced its stake in Bristol-Myers Squibb (NYSE:BMY) by 21.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,944 shares of the biopharmaceutical company’s stock after selling 1,628 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Bristol-Myers Squibb were worth $305,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. OFI Invest Asset Management acquired a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth $25,000. Milestone Investment Advisors LLC acquired a new position in Bristol-Myers Squibb during the 3rd quarter worth approximately $27,000. Blue Bell Private Wealth Management LLC raised its stake in shares of Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 200 shares in the last quarter. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $34,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter worth $40,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent analyst reports. Barclays lowered their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. BMO Capital Markets dropped their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Finally, Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Trading Down 0.8 %

Shares of NYSE BMY traded down $0.37 during midday trading on Wednesday, reaching $43.67. 11,895,172 shares of the stock were exchanged, compared to its average volume of 15,741,268. The company has a market capitalization of $88.52 billion, a P/E ratio of -14.09, a P/E/G ratio of 14.82 and a beta of 0.45. Bristol-Myers Squibb has a 52-week low of $43.33 and a 52-week high of $69.10. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The stock has a 50 day moving average price of $50.11 and a 200-day moving average price of $50.48.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.05 earnings per share. Equities research analysts expect that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 5.50%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.